deltatrials
Completed PHASE1/PHASE2 NCT00006021

Arsenic Trioxide Plus Vitamin C in Treating Patients With Recurrent or Refractory Multiple Myeloma

Phase I/II Trial of Arsenic Trioxide (As2O3) With Ascorbic Acid in the Treatment of Relapsed/Refractory Multiple Myeloma

Sponsor: National Cancer Institute (NCI)

Conditions Multiple Myeloma and Plasma Cell Neoplasm
Interventions arsenic trioxide ascorbic acid
Updated 5 times since 2017 Last updated: Dec 14, 2016 Started: Jun 30, 2000 Primary completion: May 31, 2006 Completion: Mar 31, 2007

This PHASE1/PHASE2 trial investigates Multiple Myeloma and Plasma Cell Neoplasm and is currently completed. National Cancer Institute (NCI) leads this study, which shows 5 recorded versions since 2000 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1_PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE1_PHASE2

    First recorded

Jun 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
  • University of Miami
Data source: University of Miami

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Miami, United States
  • • Miami Beach, United States